Abstract
Objective: The aim of the present study was to measure the correlation between the level of exhaled Nitric Oxide (NO) and Obstructive Sleep Apnea (OSA) severity and to evaluate its modification after Continuous Positive Airway Pressure (CPAP) treatment in severe OSA patients.
Methods: It was a descriptive and cross-sectional study. Subjects were classified by mild-moderate or severe OSA. CPAP was used for severe OSA patients and followed up for 3 months. Exhaled NO was measured in the morning after the previous night of Respiratory Polygraphy (RPG) recording.
Results: This study recruited 123 subjects, including 40 mild-moderate and 83 severe OSA patients. The level of maximum bronchial NO production (J’awNO) in patients with severe OSA was significantly higher than mild-moderate OSA [36.2 (6.1–92.2) vs. 19.6 (1.6-73.0) ppb; p=0.001)]. The level of concentration of NO in the gas phase of the alveolar (CANO) in patients with severe OSA was lower than mild-moderate OSA [5.2 (1.2-12.7) vs. 6.9 (0.8-14.0) ppb; p=0.002). The total flux of NO in the conducting airway compartment (J’awNO) and CANO were correlated with an apnea-hypopnea index (AHI) (rho=0.25 and p=0.02; rho= 0.18 and p=0.04, respectively). There was a weak significant correlation between J’awNO and nadir SpO2 in patients with OSA (rho = -0.22 and p= 0.023). After 3-month treatment with CPAP, the level of J’awNO was significantly reduced in patients with severe OSA [23.4 (12.9-44.5) vs. 33.1 (21.2-55.0); p<0.001.
Conclusion: J’awNO is proportionally increased in patients with severe OSA and reduced after treatment with CPAP. Thus, J’awNO may be used as a relevant and surrogate biomarker of severe OSA.
Keywords: Obstructive sleep apnea, exhaled NO, respiratory polygraphy, continuous positive airway pressure, J’awNO, CANO.
Graphical Abstract
Current Respiratory Medicine Reviews
Title:Exhaled Nitric Oxide as a Potential Biomarker of Continuous Positive Airway Pressure Therapy for Severe Obstructive Sleep Apnea Patients
Volume: 17 Issue: 3
Author(s): Khue Dang-Thi-Mai, Nhat-Nam Le-Dong, Khue Bui-Diem, Quan Vu-Tran-Thien, Vinh Nguyen-Nhu and Sy Duong-Quy*
Affiliation:
- Bio-Medical Research Centre, Lam Dong Medical College, Dalat, Viet Nam
- Penn State Medical College, Hershey Medical Center, PA, USA
Keywords: Obstructive sleep apnea, exhaled NO, respiratory polygraphy, continuous positive airway pressure, J’awNO, CANO.
Abstract: Objective: The aim of the present study was to measure the correlation between the level of exhaled Nitric Oxide (NO) and Obstructive Sleep Apnea (OSA) severity and to evaluate its modification after Continuous Positive Airway Pressure (CPAP) treatment in severe OSA patients.
Methods: It was a descriptive and cross-sectional study. Subjects were classified by mild-moderate or severe OSA. CPAP was used for severe OSA patients and followed up for 3 months. Exhaled NO was measured in the morning after the previous night of Respiratory Polygraphy (RPG) recording.
Results: This study recruited 123 subjects, including 40 mild-moderate and 83 severe OSA patients. The level of maximum bronchial NO production (J’awNO) in patients with severe OSA was significantly higher than mild-moderate OSA [36.2 (6.1–92.2) vs. 19.6 (1.6-73.0) ppb; p=0.001)]. The level of concentration of NO in the gas phase of the alveolar (CANO) in patients with severe OSA was lower than mild-moderate OSA [5.2 (1.2-12.7) vs. 6.9 (0.8-14.0) ppb; p=0.002). The total flux of NO in the conducting airway compartment (J’awNO) and CANO were correlated with an apnea-hypopnea index (AHI) (rho=0.25 and p=0.02; rho= 0.18 and p=0.04, respectively). There was a weak significant correlation between J’awNO and nadir SpO2 in patients with OSA (rho = -0.22 and p= 0.023). After 3-month treatment with CPAP, the level of J’awNO was significantly reduced in patients with severe OSA [23.4 (12.9-44.5) vs. 33.1 (21.2-55.0); p<0.001.
Conclusion: J’awNO is proportionally increased in patients with severe OSA and reduced after treatment with CPAP. Thus, J’awNO may be used as a relevant and surrogate biomarker of severe OSA.
Export Options
About this article
Cite this article as:
Dang-Thi-Mai Khue , Le-Dong Nhat-Nam , Bui-Diem Khue , Vu-Tran-Thien Quan , Nguyen-Nhu Vinh and Duong-Quy Sy *, Exhaled Nitric Oxide as a Potential Biomarker of Continuous Positive Airway Pressure Therapy for Severe Obstructive Sleep Apnea Patients, Current Respiratory Medicine Reviews 2021; 17 (3) . https://dx.doi.org/10.2174/1573398X17666211029095400
DOI https://dx.doi.org/10.2174/1573398X17666211029095400 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Propranolol Safety Profile in Children
Current Drug Safety Vasculitis Beyond the Kidneys
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design Transthyretin and the Systemic Inflammatory Response
Current Nutrition & Food Science The Cellular Pharmacokinetics of HIV Protease Inhibitors: Current Knowledge and Future Perspectives
Current Drug Metabolism Critical Illness in Obstetric Patients: Introduction and Epidemiology
Current Women`s Health Reviews Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Millennium Nutrient N,N-Dimethylglycine (DMG) and its Effectiveness in Autism Spectrum Disorders
Current Medicinal Chemistry Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use
Cardiovascular & Hematological Disorders-Drug Targets The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry Brain-Skin Connection: Stress, Inflammation and Skin Aging
Inflammation & Allergy - Drug Targets (Discontinued) Advanced Glycation: A Novel Outlook on Atherosclerosis
Current Pharmaceutical Design Forkhead Genes: Their Role and Impact on Ocular Developmental Diseases
Current Genomics Advancement of Targeted Ultrasound Contrast Agents and their Applications in Molecular Imaging and Targeted Therapy
Current Pharmaceutical Design Energy Provisioning and Inflammasome Activation: The Pivotal Role of AMPK in Sterile Inflammation and Associated Metabolic Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures
Current Medicinal Chemistry